Optimizing the Laboratory Diagnosis of Clostridium difficile Infection

Clinics in Laboratory Medicine

Volumn 35, Issue 2, 2015, Pages 299-312

  Gilligan, Peter H ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Algorithm; Clostridium difficile; Diarrhea; Disease outcomes; Glutamate dehydrogenase; Microbiome; Nucleic acid amplification test (NAAT); Toxin

Indexed keywords

CLOSTRIDIUM TOXIN; GLUTAMATE DEHYDROGENASE; METHOTREXATE; ZIDOVUDINE; ANTIINFECTIVE AGENT;

ANTIMICROBIAL ACTIVITY; BACTERIUM CULTURE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; FECES ANALYSIS; IMMUNOAFFINITY CHROMATOGRAPHY; INFLAMMATORY BOWEL DISEASE; LABORATORY DIAGNOSIS; NONHUMAN; NUCLEIC ACID AMPLIFICATION; PEPTOCLOSTRIDIUM DIFFICILE; PREDICTION; PRIORITY JOURNAL; REVIEW; SOLID PHASE EXTRACTION; UNITED STATES; CHEMICALLY INDUCED; CLASSIFICATION; CLOSTRIDIUM INFECTIONS; DIFFERENTIAL DIAGNOSIS; GENETICS; HUMAN; ISOLATION AND PURIFICATION; PATHOGENICITY; PRACTICE GUIDELINE; PROCEDURES; SENSITIVITY AND SPECIFICITY;

ANTI-INFECTIVE AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIAGNOSIS, DIFFERENTIAL; FALSE POSITIVE REACTIONS; GUIDELINES AS TOPIC; HUMANS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 84929949214     PISSN: 02722712     EISSN: 15579832     Source Type: Journal    
DOI: 10.1016/j.cll.2015.02.003     Document Type: Review

References (59)

1. Magill S.S., Edwards J.R., Bamberg W., et al. Multistate point-prevalence survey of health care-associated infections. NEngl J Med 2014, 370:1198-1208.
2. Peery A.F., Dellon E.S., Lund J., et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012, 143:1179-1187.e1-3.
3. Lessa F.C., Gould C.V., McDonald L.C. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis 2012, 55(Suppl 2):S65-S70.
4. Walker A.S., Eyre D.W., Wyllie D.H., et al. Relationship between bacterial strain type, host biomarkers, and mortality in Clostridium difficile infection. Clin Infect Dis 2013, 56:1589-1600.
5. Burnham C.A., Carroll K.C. Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories. Clin Microbiol Rev 2013, 26:604-630.
6. Bartlett J.G., Moon N., Chang T.W., et al. Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology 1978, 75:778-782.
7. Surawicz C.M., Brandt L.J., Binion D.G., et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013, 108:478-498. [quiz: 99].
8. Taur Y., Pamer E.G. Harnessing microbiota to kill a pathogen: fixing the microbiota to treat Clostridium difficile infections. Nat Med 2014, 20:246-247.
9. Schubert A.M., Rogers M.A., Ring C., et al. Microbiome data distinguish patients with Clostridium difficile infection and non-C. difficile-associated diarrhea from healthy controls. MBio 2014, 5(3). e01021-14.
10. Petrof E.O., Gloor G.B., Vanner S.J., et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut. Microbiome 2013, 1:3.
11. Youngster I., Russell G.H., Pindar C., et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 2014, 312:1772-1778.
12. van Nood E., Vrieze A., Nieuwdorp M., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. NEngl J Med 2013, 368:407-415.
13. Kassam Z., Lee C.H., Yuan Y., et al. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013, 108:500-508.
14. Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infections Updated guidance on the diagnosis and reporting of Clostridium difficile 2012, National Health Service, United Kingdom.
15. Gilligan P. Contemporary approaches for the laboratory diagnosis of Clostridium difficile infections. Semin Colon Rectal Surg 2014, 25:137-142.
16. Kutty P.K., Woods C.W., Sena A.C., et al. Risk factors for and estimated incidence of community-associated Clostridium difficile infection, North Carolina, USA. Emerg Infect Dis 2010, 16:197-204.
17. McCarthy K., Johnston S., Hepworth C. Clostridium difficile-associated colitis following the use of Chinese medicine. BMJ Case Rep 2009, 2009. 10.1136/bcr.08.2008.0716.
18. Dubberke E.R., Han Z., Bobo L., et al. Impact of clinical symptoms on interpretation of diagnostic assays for Clostridium difficile infections. JClin Microbiol 2011, 49:2887-2893.
19. Caroff D.A., Edelstein P.H., Hamilton K., et al. The Bristol Stool Scale and its relationship to Clostridium difficile infection. JClin Microbiol 2014, 52:3437-3439.
20. Brecher S.M., Novak-Weekley S.M., Nagy E. Laboratory diagnosis of Clostridium difficile infections: there is light at the end of the colon. Clin Infect Dis 2013, 57:1175-1181.
21. Schutze G.E., Willoughby R.E. Clostridium difficile infection in infants and children. Pediatrics 2013, 131:196-200.
22. Viscidi R., Willey S., Bartlett J.G. Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology 1981, 81:5-9.
23. Galdys A.L., Nelson J.S., Shutt K.A., et al. Prevalence and duration of asymptomatic Clostridium difficile carriage among healthy subjects in Pittsburgh, Pennsylvania. JClin Microbiol 2014, 52:2406-2409.
24. Guerrero D.M., Becker J.C., Eckstein E.C., et al. Asymptomatic carriage of toxigenic Clostridium difficile by hospitalized patients. JHosp Infect 2013, 85:155-158.
25. Alasmari F., Seiler S.M., Hink T., et al. Prevalence and risk factors for asymptomatic Clostridium difficile carriage. Clin Infect Dis 2014, 59:216-222.
26. Koo H.L., Van J.N., Zhao M., et al. Real-time polymerase chain reaction detection of asymptomatic Clostridium difficile colonization and rising C. difficile-associated disease rates. Infect Control Hosp Epidemiol 2014, 35:667-673.
27. Willems L., Porcher R., Lafaurie M., et al. Clostridium difficile infection after allogeneic hematopoietic stem cell transplantation: incidence, risk factors, and outcome. Biol Blood Marrow Transplantant 2012, 18:1295-1301.
28. Khanna S., Pardi D.S., Rosenblatt J.E., et al. An evaluation of repeat stool testing for Clostridium difficile infection by polymerase chain reaction. JClin Gastroenterol 2012, 46:846-849.
29. Nistico J.A., Hage J.E., Schoch P.E., et al. Unnecessary repeat Clostridium difficile PCR testing in hospitalized adults with C. difficile-negative diarrhea. Eur J Clin Microbiol Infect Dis 2012, 32:97-99.
30. D'Agostino R.B., Collins S.H., Pencina K.M., et al. Risk estimation for recurrent Clostridium difficile infection based on clinical factors. Clin Infect Dis 2014, 58:1386-1393.
31. Leav B.A., Blair B., Leney M., et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 2009, 28:965-969.
32. Chang T.W., Lin P.S., Gorbach S.L., et al. Ultrastructural changes of cultured human amnion cells by Clostridium difficile toxin. Infect Immun 1979, 23:795-798.
33. Lyerly D.M., Krivan H.C., Wilkins T.D. Clostridium difficile: its disease and toxins. Clin Microbiol Rev 1988, 1:1-18.
34. George W.L., Sutter V.L., Citron D., et al. Selective and differential medium for isolation of Clostridium difficile. JClin Microbiol 1979, 9:214-219.
35. Lister M., Stevenson E., Heeg D., et al. Comparison of culture based methods for the isolation of Clostridium difficile from stool samples in a research setting. Anaerobe 2014, 28:226-229.
36. Lyras D., O'Connor J.R., Howarth P.M., et al. Toxin B is essential for virulence of Clostridium difficile. Nature 2009, 458:1176-1179.
37. Kuehne S.A., Cartman S.T., Heap J.T., et al. The role of toxin A and toxin B in Clostridium difficile infection. Nature 2010, 467:711-713.
38. Ticehurst J.R., Aird D.Z., Dam L.M., et al. Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin. JClin Microbiol 2006, 44:1145-1149.
39. Gilligan P.H. Is a two-step glutamate dehyrogenase antigen-cytotoxicity neutralization assay algorithm superior to the premier toxin A and B enzyme immunoassay for laboratory detection of Clostridium difficile?. JClin Microbiol 2008, 46:1523-1525.
40. Fenner L., Widmer A.F., Goy G., et al. Rapid and reliable diagnostic algorithm for detection of Clostridium difficile. JClin Microbiol 2008, 46:328-330.
41. Quinn C.D., Sefers S.E., Babiker W., et al. C. Diff Quik Chek complete enzyme immunoassay provides a reliable first-line method for detection of Clostridium difficile in stool specimens. JClin Microbiol 2009, 48:603-605.
42. Sharp S.E., Ruden L.O., Pohl J.C., et al. Evaluation of the C. Diff Quik Chek Complete Assay, a new glutamate dehydrogenase and A/B toxin combination lateral flow assay for use in rapid, simple diagnosis of Clostridium difficile disease. JClin Microbiol 2010, 48:2082-2086.
43. O'Horo J.C., Jones A., Sternke M., et al. Molecular techniques for diagnosis of Clostridium difficile infection: systematic review and meta-analysis. Mayo Clin Proc 2012, 87:643-651.
44. Deshpande A., Pasupuleti V., Rolston D.D., et al. Diagnostic accuracy of real-time polymerase chain reaction in detection of Clostridium difficile in the stool samples of patients with suspected Clostridium difficile infection: a meta-analysis. Clin Infect Dis 2011, 53:e81-e90.
45. College of American Pathologists. D-A Bacteriology participant survey. Northfield (IL): American College of Pathologists; 2014.
46. Culbreath K., Ager E., Nemeyer R.J., et al. Evolution of testing algorithms at a university hospital for detection of Clostridium difficile infections. JClin Microbiol 2012, 50:3073-3076.
47. Khare R., Espy M.J., Cebelinski E., et al. Comparative evaluation of two commercial multiplex panels for detection of gastrointestinal pathogens by use of clinical stool specimens. JClin Microbiol 2014, 52:3667-3673.
48. Planche T.D., Davies K.A., Coen P.G., et al. Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection. Lancet Infect Dis 2013, 13:936-945.
49. Beaulieu C., Dionne L.L., Julien A.S., et al. Clinical characteristics and outcome of patients with Clostridium difficile infection diagnosed by PCR versus a three-step algorithm. Clin Microbiol Infect 2014, 20:1067-1073.
50. Landry M.L., Ferguson D., Topal J. Comparison of Simplexa universal direct PCR with cytotoxicity assay for diagnosis of Clostridium difficile infection: performance, cost, and correlation with disease. JClin Microbiol 2014, 52:275-280.
51. Baker I., Leeming J.P., Reynolds R., et al. Clinical relevance of a positive molecular test in the diagnosis of Clostridium difficile infection. JHosp Infect 2013, 84:311-315.
52. Leslie J.L., Cohen S.H., Solnick J.V., et al. Role of fecal Clostridium difficile load in discrepancies between toxin tests and PCR: is quantitation the next step in C. difficile testing?. Eur J Clin Microbiol Infect Dis 2012, 31:3295-3299.
53. Polage C.R., Chin D.L., Leslie J.L., et al. Outcomes in patients tested for Clostridium difficile toxins. Diagn Microbiol Infect Dis 2012, 74:369-373.
54. Beck E.T., Buchan B.W., Riebe K.M., et al. Multicenter evaluation of the Quidel Lyra Direct C. difficile nucleic acid amplification assay. JClin Microbiol 2014, 52:1998-2002.
55. Barbut F., Surgers L., Eckert C., et al. Does a rapid diagnosis of Clostridium difficile infection impact on quality of patient management?. Clin Microbiol Infect 2013, 20:136-144.
56. Sydnor E.R., Lenhart A., Trollinger B., et al. Antimicrobial prescribing practices in response to different Clostridium difficile diagnostic methodologies. Infect Control Hosp Epidemiol 2011, 32:1133-1136.
57. Gould C.V., Edwards J.R., Cohen J., et al. Effect of nucleic acid amplification testing on population-based incidence rates of Clostridium difficile infection. Clin Infect Dis 2013, 57:1304-1307.
58. Williamson D.A., Basu I., Freeman J., et al. Improved detection of toxigenic Clostridium difficile using the Cepheid Xpert C difficile assay and impact on C difficile infection rates in a tertiary hospital: a double-edged sword. Am J Infect Control 2012, 41:270-272.
59. Longtin Y., Trottier S., Brochu G., et al. Impact of the type of diagnostic assay on Clostridium difficile infection and complication rates in a mandatory reporting program. Clin Infect Dis 2013, 56:67-73.